CLANOTECH AB

clanotech-ab-logo

Clanotech is active in ophthalmology. Clanotechโ€™s development strategy spans from indications with orphan drug opportunities such as developing safe and target specific anti-scarring treatment in glaucoma surgery techniques to therapeutic areas with high commercial potential as wet Age Related Macular Degeneration, proliferative diabetic retinopathy, proliferative vitreoretinopathy, pterygium etc..

#Website #More

CLANOTECH AB

Industry:
Biotechnology Health Care

Address:
Solna, Stockholms Lan, Sweden

Country:
Sweden

Website Url:
http://www.clanotech.se

Status:
Active

Email Addresses:
[email protected]

Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS ASP.NET IIS IIS 10 Classic ASP


Official Site Inspections

http://www.clanotech.se

Unable to get host informations!!!

Loading ...

More informations about "Clanotech AB"

Clanotech AB - Crunchbase Company Profile & Funding

Clanotech AB is active in ophthalmology. Clanotech is active in ophthalmology. Clanotechโ€™s development strategy spans from indications with orphan drug opportunities such as โ€ฆSee details»

ClanoTech AB - Företagsinformation - allabolag.se

ClanoTech AB,556706-6658 - På allabolag.se hittar du , bokslut, nyckeltal, styrelse, Status, adress mm för ClanoTech AB. Sök ... Gratis Med allabolag.se konto Hämta Köp utan โ€ฆSee details»

Clanotech Company Profile 2024: Valuation, Funding & Investors

Clanotech General Information Description. Developer of pharmaceuticals designed to treat cancer and age-related muscular degeneration. The company's pharmaceuticals are strategy โ€ฆSee details»

ClanoTech AB - Drug pipelines, Patents, Clinical trials - Synapse

Explore ClanoTech AB with its drug pipeline, therapeutic area, technology platform, , Technology Platform:Small molecule drug, Drug:CLT-28643. ... www.clanotech.se. Last update 01 Nov โ€ฆSee details»

Clanotech AB - VentureRadar

Clanotech is developing small molecules for alpha5beta1-integrin inhibition for treatment of diseases of the eye. ... Find out more about Clanotech AB, Cancer Therapeutics and โ€ฆSee details»

Clanotech AB Company Profile - Dun & Bradstreet

Find company research, competitor information, contact details & financial data for Clanotech AB of Solna, Stockholm. Get the latest business insights from Dun & Bradstreet.See details»

Clanotech - Company Profile - Tracxn

Oct 23, 2024 Clanotech ranks 160th among 201 active competitors. 69 of its competitors are funded while 57 have exited. Overall, Clanotech and its competitors have raised over $5.46B โ€ฆSee details»

Clanotech AB - Crunchbase

Clanotech AB is active in ophthalmology. Start Free Trial . Chrome ExtensionSee details»

CLANOTECH AB | TREA

Explore innovation relationships and map ideas to the unified knowledge graphSee details»

Clanotech, Solna, SE | Company Information

Infobel Sweden Industrial Production & Supplies Solna Clanotech. Categories. Industrial Production & Supplies (111) Other Companies & Services (6) Health & Medicine (4) Computer โ€ฆSee details»

Clanotech AB - BioCentury Company Profiles - BCIQ

Apr 13, 2015 Clanotech AB - BioCentury Company Profiles for the biopharma industrySee details»

Clanotech - Products, Competitors, Financials, Employees, โ€ฆ

Use the CB Insights Platform to explore Clanotech's full profile. Clanotech - Products, Competitors, Financials, Employees, Headquarters Locations Technology VendorsSee details»

Clanotech AB - Tech Stack, Apps, Patents & Trademarks

Organization. Clanotech AB . Connect to CRM . Save . Summary. People. Technology. Signals & News. Similar Companies. Highlights. Active Tech Count 8. About. Clanotech AB is actively โ€ฆSee details»

Clanotech granted Orphan Drug Designation by the U.S. FDA

Mar 27, 2015 For more information on the Orphan Drug Designation and Clanotech please visit: www.clanotech.se For further information, please contact: Jim Van heusden, CEO, Karolinska โ€ฆSee details»

Clanotech AB Receives Orphan Drug Designation In The U.S.

Mar 27, 2015 Clanotech is a Swedish biotech company active in ophthalmology. Clanotech development strategy spans from niche indications with orphan drug opportunities such as โ€ฆSee details»

Karolinska Development's Clanotech receives EU drug designation

Oct 20, 2014 * Clanotech AB announced that its anti-fibrotic and anti-angiogenic candidate drug CLT-28643 received orphan drug designation by the European Medicines Agency for โ€ฆSee details»

CLT-28643 - Drug Targets, Indications, Patents - Synapse - Patsnap

Purpose To evaluate the therapeutic potential of the small molecule integrin ฮฑ5ฮฒ1 inhibitor, CLT-28643, to improve the filtering surgery outcome in a mouse model. Different dose regimens โ€ฆSee details»

Clanotech Receives Orphan Drug Designation in the U.S.

Mar 28, 2015 Clanotech is now preparing for a phase I/II trial with CLT-28643โ€, said Patrizia Caldirola, CEO, Clanotech. Clanotechโ€™s lead compound, an ฮฑ5ฮฒ1-integrin antagonist, has anti โ€ฆSee details»

Clanotech Drug Gets FDA Orphan Label - NLS - Nordic Life Science

Mar 30, 2015 Clanotech ABโ€™s candidate drug CLT-28643 has received orphan drug designation by the U.S. Food and Drug Administration (FDA) for prevention of scarring after glaucoma โ€ฆSee details»

CLT 28643 - AdisInsight - Springer

Aug 28, 2021 CLT 28643 is an alpha-5-beta-1 (ฮฑ5ฮฒ1) integrin inhibitor, being developed by Clanotech for the treatment of eye disorders to treat scarring after glaucoma CLT 28643 Next โ€ฆSee details»